Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Neal Lakdawala, M.D.

Co-Author

This page shows the publications co-authored by Neal Lakdawala and Steven Colan.
Connection Strength

1.309
  1. Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2021 02; 14(1):e003062.
    View in: PubMed
    Score: 0.235
  2. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2020 01 01; 5(1):83-91.
    View in: PubMed
    Score: 0.221
  3. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012 Oct 01; 5(5):503-10.
    View in: PubMed
    Score: 0.133
  4. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011 Dec 01; 108(11):1606-13.
    View in: PubMed
    Score: 0.124
  5. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):320-9.
    View in: PubMed
    Score: 0.111
  6. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 Oct; 27(10):1818-1824.
    View in: PubMed
    Score: 0.062
  7. Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genet Med. 2021 07; 23(7):1281-1287.
    View in: PubMed
    Score: 0.060
  8. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020 10; 13(5):396-405.
    View in: PubMed
    Score: 0.058
  9. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020 04 28; 141(17):1371-1383.
    View in: PubMed
    Score: 0.056
  10. Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 03 19; 139(12):1559-1560.
    View in: PubMed
    Score: 0.052
  11. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 10 02; 138(14):1387-1398.
    View in: PubMed
    Score: 0.050
  12. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016 Nov 15; 102(22):1805-1812.
    View in: PubMed
    Score: 0.044
  13. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb; 3(2):180-8.
    View in: PubMed
    Score: 0.039
  14. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun; 6(3):230-7.
    View in: PubMed
    Score: 0.035
  15. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010 Aug 05; 363(6):552-63.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.